Mycophenolate Mofetil Sandoz

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Sandoz, is an antimetabolite presented as an oral tablet for oral use. It is employed to prevent acute rejection in kidney, heart and liver transplantation and to treat lupus nephritis in adult patients.

GNH USA supplies Mycophenolate Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across regions.

Mycophenolate Mofetil is an immunosuppressant used in conditions where immune modulation is required.

Kidney transplantation: helps prevent acute graft rejection by inhibiting lymphocyte proliferation. Heart transplantation: reduces the risk of early rejection episodes through immunosuppression. Liver transplantation: maintains graft function by suppressing T‑cell activity. Lupus nephritis: decreases renal inflammation and proteinuria by limiting immune complex formation.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to